Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia

In acute psychotic schizophrenia patients we investigated if the combination of triiodothyronine (T3) plus risperidone was more effective when compared to risperidone monotherapy. Thirty-two in-patients meeting the DSM-IV-TR diagnostic criteria for schizophrenia and without thyroid disease received risperidone (flexibly adjusted dose for tolerability) and were randomized to additionally receive either T3 (25 μg daily; risperidone plus T3 group) or placebo (risperidone plus placebo group). Treatment lasted until meeting the response to treatment criteria defined as score of ≤3 on the Clinical Global Impression Severity and Improvement scales. Acute psychotic episode symptom severity was evaluated using the Brief Psychiatric Rating Scale (BPRS) at treatment initiation and at the final study assessment. Fourteen patients were randomized to receive risperidone plus T3 and eighteen to receive risperidone plus placebo. The time until treatment response was shorter in the risperidone plus T3 group relative to the risperidone plus placebo group (25.5 ± 4.4 days vs 32.2 ± 8.2 days, respectively; p = 0.001). Moreover, there was a greater reduction of BPRS-total score (p = 0.01) in the risperidone plus T3 group relative to the risperidone plus placebo group. Treatment with T3 was associated with shorter time to treatment response (β = −0.440, p = 0.022) and with greater improvement in BPRS score (β = 0.240, p = 0.053), independent of patients' gender, age, baseline BPRS score and mean risperidone dose. The study confirms that addition of T3 to risperidone was associated with accelerated and enhanced treatment response in acutely psychotic schizophrenic patients.     

Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine

Recent studies have shown benefits for the supplementation of folic acid in schizophrenic patients. The aim of this study was to evaluate the effects of folic acid addition on adult rats, over a period of 7 or 14 days. It also sets out to verify any potential protective action using an animal model of schizophrenia induced by ketamine, in behavioral and biochemical parameters. This study used two protocols (acute and chronic) for the administration of ketamine at a dose of 25 mg/kg (i.p.). The folic acid was given by oral route in doses of 5, 10 and 50 mg/kg, once daily, for 7 and/or 14 days in order to compare the protective effects of folic acid. Thirty minutes after the last administration of ketamine, the locomotor and social interaction activities were evaluated, and immediately the brain structure were removed for biochemical analysis. In this study, ketamine was administered in a single dose or in doses over the course of 7 days increasing the animal’s locomotion. This study showed that the administration of folic acid over 7 days was unable to prevent hyper locomotion. In contrast, folic acid (10 and 50 mg/kg) administrated over a period of 14 days, was able to partially prevent the hyper locomotion. Our data indicates that both acute and chronic administrations of ketamine increased the time to first contact between the animals, while the increased latency for social contact was completely prevented by folic acid (5, 10 and 50 mg/kg). Chronic and acute administrations of ketamine also increased lipid peroxidation and protein carbonylation in brain. Folic acid (10 and 50 mg/kg) supplements showed protective effects on the oxidative damage found in the different brain structures evaluated. All together, the results indicate that nutritional supplementation with folic acid provides promising results in an animal model of schizophrenia induced by ketamine.     

乌灵胶囊联合棕榈酸帕利哌酮注射剂对精神分裂症患者睡眠质量和神经营养因子的影响

【摘要】 目的 探讨乌灵胶囊联合棕榈酸帕利哌酮注射剂对精神分裂症患者睡眠质量和神经营养因子的影响。方法 选择2017年2月-2018年4月于我院就诊的精神分裂症患者80例,按照随机数字表法分为观察组和对照组,对照组接受棕榈酸帕利哌酮注射剂治疗,观察组在对照组基础上加用乌灵胶囊,治疗13周后观察两组临床疗效、PANSS评分、睡眠质量以及神经营养因子水平变化。结果 两组总有效率比较差异无统计学意义（P>0.05）;治疗后两组PANSS评分较治疗前均明显降低（P<0.01）,组间比较差异无统计学意义（P>0.05）;治疗前后对照组PSQI评分比较差异无统计学意义（P>0.05）,治疗后观察组PSQI评分较治疗前明显降低（P<0.01）,且明显低于对照组（P<0.01）;治疗后两组BDNF、NGF、NT-3水平较治疗前明显升高（P<0.01）,且观察组明显高于对照组（P<0.05）。结论 乌灵胶囊联合棕榈酸帕利哌酮注射剂治疗精神分裂症效果显著,可明显改善患者睡眠质量和神经营养因子水平。     

残留期、衰退期精神分裂症患者的人格特征

目的 :测量残留期、衰退期精神分裂症患者的人格特征 ,观察精神分裂症所致人格改变的特点及偏离程度。方法 :采用修订卡特尔十六种人格因素量表 (简称 16PF)对 30例残留期、衰退期精神分裂症患者 (研究组 )和30例非残留期、衰退期精神分裂症患者 (对照组 )进行对照分析。结果 :研究组与对照组对比 ,低恃强E、低兴奋F有极显著性差异 (P <0 0 1) ,低乐群A、低稳定C、低敢为H、高独立Q2、低紧张Q4有显著性差异 (P <0 0 5 ) ,其他 9种人格因素无显著性差异 (P >0 0 5 )。结论 :研究组与对照组人格特征存在差异 ,这些差异及差异程度是精神分裂症疾病所致     

早发精神分裂症血清S100B蛋白浓度测定及其临床意义

目的：探讨血清S100B蛋白水平在早发精神分裂症患儿中的表达及意义。方法方便选择2015年5月—2016年1月间河南省精神病医院收治的90例早发精神分裂症患儿为观察组,同期72名健康儿童为对照组。采用Elisa法对两组儿童血清S100B水平进行检测。并采用威斯康星卡片分类测验(WCST)评估两组的认知功能指标(完成分数、错误应答数、完成第一个分类所需应答数、持续性错误数、持续性应答、非持续错误数)情况。结果观察组血清S100B水平为(0.163±0.040)μg/L显著性高于对照组的(0.129±0.033)μg/L(P<0.05)。观察组WCST各指标评分分别为(4.52±1.44)分、(44.37±12.46)分、(23.94±12.05)分、(8.86±3.14)分、(18.62±6.38)分、(35.17±14.33)分,均显著低于对照组的(5.49±1.27)分、(30.28±15.03)分、(16.07±9.17)分、(6.15±1.33)分、(12.65±5.34)分、(26.84±12.76)分(P<0.05)。血清S100B与WCST的非持续性错误、持续性应答、数错误应答数呈正相关性(r=0.403、0.368、0.364; P<0.05)。结论早发精神分裂症患儿血清S100B水平明显高于正常儿童,并与认知功能障碍呈正相关。     

户外运动对伴骨质疏松症精神分裂症患者心理健康及生活质量的影响

目的：探究户外运动对伴骨质疏松症精神分裂症患者心理健康及生活质量的影响。方法随机选取2014年2月-2016年2月该院60例伴骨质疏松症精神分裂症患者为研究对象,随机分为观察组和对照组,每组30例,给予对照组常规膳食和心理干预,观察组在此基础上给予户外运动干预;比较两组治疗前后心理健康及生活质量改善情况。结果两组治疗前SCL-90各因子评分比较差异无统计学意义(P>0.05),干预后各因子评分明显降低(P<0.05),且观察组躯体化、强迫症状、人际关系敏感、抑郁、焦虑、敌对、恐怖、偏执、精神病性显著低于对照组(P<0.05)。两组干预前SQLS各维度评分及总均分比较差异无统计学意义(P>0.05),干预后SQLS各维度评分及总均分明显降低(P<0.05),观察组心理社会、动力和精力及总均分显著低于对照组(P<0.05)。结论户外运动结合相关基础护理干预可调节伴骨质疏松症精神分裂症患者心理状态,提高其生活质量。     

利培酮与齐拉西酮治疗精神分裂症的疗效对比

目的：探析利培酮与齐拉西酮治疗精神分裂症的疗效。方法整群选取该院2013年1月—2015年12月收治的88例精神分裂症患者,将其随机分为治疗组和对照组,各为44例,治疗组采取齐拉西酮治疗,对照组给予利培酮治疗,对比两组治疗效果及不良反应。结果治疗组治疗后PANSS评分(45.3±7.8)分,与对照组(55.6±6.3)分比较差异明显,P<0.05;治疗组不良反应发生率43.18%与对照组63.64%比较差异有统计学意义,P<0.05。结论齐拉西酮治疗精神分裂症的疗效优于利培酮,不良反应少,值得临床应用。     

齐拉西酮与奥氮平对初诊精神分裂症患者急性期的疗效和代谢影响对比观察

目的：探讨初诊精神分裂症患者分别采用齐拉西酮与奥氮平的治疗措施及对糖脂代谢的影响。方法整群抽取2014年10月—2015年10月该院收治的118例初诊精神分裂症患者作为研究对象,依据入院顺序的单双号法将其随机分为观察组(n=59)与对照组(n=59),观察组患者予以齐拉西酮的治疗措施,对照组患者则予以奥氮平的治疗措施,分别观察两组患者治疗后的临床效果,并观察糖脂代谢指标的变化情况。结果观察组患者的FBS(4.5±0.3) mmol/L、TC(1.2±0.3) mmol/L、TG(4.0±0.4) mmol/L、INS(9.5±1.0×103)μU/L、LDL(2.0±0.2) mmol/L、HDL(1.3±0.2) mmol/L以IRI(1.9±0.3) mmol/L等指标均显著低于对照组,组间比较差异具有统计学意义(P<0.05)。结论初诊精神分裂症患者采用齐拉西酮药物较奥氮平具有更高的临床疗效,值得推广。     

齐拉西酮与利培酮治疗精神分裂症对血糖影响的对照研究

目的：探讨齐拉西酮与利培酮在精神分裂症治疗过程中对其血糖的影响。方法整群选取该院于2014年8月—2015年9月收治的93例精神分裂症患者纳入研究,按入院先后分为治疗组50例和对照组43例,分别采用齐拉西酮和利培酮对治疗组和对照组进行治疗。对比治疗前后两组患者的阴性阳性症状量表(PANSS)评分及空腹血糖的变化情况。结果治疗前,两组患者的PANSS评分及空腹血糖情况比较差异无统计学意义(P>0.05)。治疗期间,两组患者的PANSS评分逐渐降低,各阶段PANSS评分比较没有统计学意义(P>0.05)。而对照组患者在治疗后2、4、8周的空腹血糖水平分别为(6.13±1.16)mmol/L、(6.28±1.13)mmol/L、(6.31±1.03)mmol/L,其空腹血糖水平明显上升,而观察组在治疗后2、4、8周的空腹血糖水平分别为(5.71±0.68)mmol/L、(5.86±0.71)mmol/L、(5.92±0.92)mmol/L,基本保持稳定,组间比较差异有统计学意义(P<0.05)。结论齐拉西酮与利培酮在治疗精神分裂症上疗效相当,但齐拉西酮在治疗过程中对患者的血糖水平影响较小,在临床用药上应优先选择齐拉西酮。     

精神分裂症患者血清中犬尿氨酸及犬尿氨酸-3-单加氧酶浓度变化及临床意义

目的：研究精神分裂症（Schizophrenia,SZ）患者血清犬尿氨酸（Kynurenine,KYN）及犬尿氨酸-3-单加氧酶（Kynurenine 3-Monooxygenase,KMO）的浓度变化及临床意义。方法：采用酶联免疫吸附法检测55例 SZ 患者和33例正常对照（CTR）组血清中 KYN 和 KMO 浓度并计算 KYN/KMO 的比值。结果：SZ 患者血清 KYN 含量显著高于正常对照组;SZ 患者血清 KMO 含量显著低于正常对照组;SZ 组男性患者和 CTR 组男性对照血清 KMO 含量较同组内的女性显著降低;SZ 组男性和女性患者血清 KYN 含量均显著高于相应的 CTR 组男性和女性对照;SZ 组女性患者血清 KMO 含量较 CTR 组女性对照显著降低。结论：血清 KYN 和 KMO 水平可为 SZ 的临床诊断和治疗提供实验依据。